References of "FOIDART, Jean-Michel"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailExpression et localisation spatio-temporelle de KISS1 et de son récepteur KISSR dans le placenta normal et pathologique.
VALDES SOCIN, Hernan Gonzalo ULg; Munaut, Carine ULg; CHAVEZ, Viviana ULg et al

Poster (2012, October)

Objectif : Etudier l’expression de KISS1 (métastatine) et de son récepteur KISS1R lors de la grossesse normale et pathologique. Matériels et méthodes : Nous avons étudié la localisation de KISS1 et KISS1R ... [more ▼]

Objectif : Etudier l’expression de KISS1 (métastatine) et de son récepteur KISS1R lors de la grossesse normale et pathologique. Matériels et méthodes : Nous avons étudié la localisation de KISS1 et KISS1R par immunohistochimie dans des placentas normaux (1 er et 3 ème trimestre). Par RT-PCR quantitative, nous avons évalué le niveau d’expression des ARNm dans les placentas et les lits placentaires correspondants. Les niveaux d’expression de ARNm ont été comparés entre les grossesses normales (GN, n=13) et les grossesses spathologiques Prééclampsiques -PE-, n=17 et retard de croissance intrautérine -RCIU-, n=9). Résultats : Au premier trimestre des GN, KISS1 est majoritairement localisé dans les syncitiotrophoblastes, alors que KISS1R est détecté dans le mesenchyme villositaire. Au cours du troisième trimestre, KISS1 est uniquement localisé dans le syncitiotrophoblaste au contact avec la décidue et dans le mésenchyme villositaire et KISS1R est détecté dans le trophoblaste extra-villeux ainsi que dans quelques cellules de la décidue. Les analyses par RT-PCR mettent en évidence une expression plus importante des ARNm de KISS1 (p<0,001) et de KISS1R (p=0.039) dans les placentas (GN,PE et RCIU) par rapport aux lits placentaires correspondants. Les niveaux d’expression de KISS1 et KISS1R ne sont pas, cependant, significativement modulés dans les grossesses pathologiques. Conclusions : Par immunohistochimie, nos résultats indiquent une expression spatiotemporelle différente pour KISS1 et KISS1R entre le 1 er et 3 ème trimestre des grossesses normales. Nous n’avons pas mis en évidence de modulation de l’expression des ARNm dans les grossesses pathologiques. [less ▲]

Detailed reference viewed: 51 (9 ULg)
Full Text
See detailImplant comprising a core and a tube encasing the core
Donnez, Jacques; Van Langendonkt, Anne; Defrère, Sylvie et al

Patent (2012)

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene ... [more ▼]

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer; - a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer; and - at least one active ingredient; wherein said at least one active ingredient is selected from the group comprising celecoxib, sulindac, tamoxifen, oestrogen, oestradiol, ethinyl oestradiol, mestranol, dienogest, norgestrel, levonorgestrel, desogestrel, norgestimate, ethynodiol diacetate, leuprorelin, buserelin, gonrelin, triptorelin, nafarelin, deslorelin, histrelin, and supprelin; and with the proviso that when the sealant is said at least one hydrogelpolymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament. In particular, the invention relates to an implant for use in the treatment of endometriosis. [less ▲]

Detailed reference viewed: 72 (19 ULg)
Full Text
See detailImplant comprising a core and a tube encasing the core
Donnez, Jacques; Van Langendonkt, Anne; Defrère, Stéphanie et al

Patent (2012)

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene ... [more ▼]

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer; - a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer; and - at least one active ingredient; with the proviso that when the sealant is said at least one hydrogel polymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament. In particular, the invention relates to an implant for use in the treatment of endometriosis. [less ▲]

Detailed reference viewed: 54 (18 ULg)
Full Text
Peer Reviewed
See detailMatrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase.
Detry, Benoît ULg; Erpicum, Charlotte ULg; Paupert, Jenny ULg et al

in Blood (2012), 119(21), 5048-56

Lymphatic dysfunctions are associated with several human diseases, including lymphedema and metastatic spread of cancer. Although it is well recognized that lymphatic capillaries attach directly to ... [more ▼]

Lymphatic dysfunctions are associated with several human diseases, including lymphedema and metastatic spread of cancer. Although it is well recognized that lymphatic capillaries attach directly to interstitial matrix mainly composed of fibrillar type I collagen, the interactions occurring between lymphatics and their surrounding matrix have been overlooked. In this study, we demonstrate how matrix metalloproteinase (MMP)–2 drives lymphatic morphogenesis through Mmp2-gene ablation in mice, mmp2 knockdown in zebrafish and in 3D-culture systems, and through MMP2 inhibition. In all models used in vivo (3 murine models and thoracic duct development in zebrafish) and in vitro (lymphatic ring and spheroid assays), MMP2 blockage or down-regulation leads to reduced lymphangiogenesis or altered vessel branching. Our data show that lymphatic endothelial cell (LEC) migration through collagen fibers is affected by physical matrix constraints (matrix composition, density and cross-linking). Transmission electron microscopy (TEM) and confocal reflection microscopy using DQ-collagen highlight the contribution of MMP2 to mesenchymal-like migration of LEC associated with collagen fiber remodeling. Our findings provide new mechanistic insight into how LEC negotiate an interstitial type I collagen barrier and reveal an unexpected MMP2-driven collagenolytic pathway for lymphatic vessel formation and morphogenesis. [less ▲]

Detailed reference viewed: 213 (72 ULg)
Full Text
Peer Reviewed
See detailThe actors of human implantation: gametes, embryo and endometrium
Gridelet, Virginie ULg; GASPARD, Olivier ULg; Polese, Barbara ULg et al

in Violin Pereira, Luis Antonio (Ed.) Embryology - Updates and Highlights on Classic Topics (2012)

Detailed reference viewed: 41 (9 ULg)
Full Text
Peer Reviewed
See detailDifferential expression of Vegfr-2 and its soluble form in preeclampsia.
Munaut, Carine ULg; LORQUET, Sophie ULg; Pequeux, Christel ULg et al

in PLoS ONE (2012), 7(3), 33475

Background: Several studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably ... [more ▼]

Background: Several studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and soluble endoglin (sEng), as well as to decreased PlGF. Recently, soluble VEGF type 2 receptor (sVEGFR-2) has emerged as a crucial regulator of lymphangiogenesis. To date, however, there is a paucity of information on the changes of VEGFR-2 that occur during the clinical onset of PE. Therefore, the aim of our study was to characterize the plasma levels of VEGFR-2 in PE patients and to perform VEGFR-2 immunolocalization in placenta. METHODOLOGY/PRINCIPAL FINDINGS: By ELISA, we observed that the VEGFR-2 plasma levels were reduced during PE compared with normal gestational age matched pregnancies, whereas the VEGFR-1 and Eng plasma levels were increased. The dramatic drop in the VEGFR-1 levels shortly after delivery confirmed its placental origin. In contrast, the plasma levels of Eng and VEGFR-2 decreased only moderately during the early postpartum period. An RT-PCR analysis showed that the relative levels of VEGFR-1, sVEGFR-1 and Eng mRNA were increased in the placentas of women with severe PE. The relative levels of VEGFR-2 mRNA as well as expressing cells, were similar in both groups. We also made the novel finding that a recently described alternatively spliced VEGFR-2 mRNA variant was present at lower relative levels in the preeclamptic placentas. CONCLUSIONS/SIGNIFICANCE: Our results indicate that the plasma levels of anti-angiogenic factors, particularly VEGFR-1 and VEGFR-2, behave in different ways after delivery. The rapid decrease in plasma VEGFR-1 levels appears to be a consequence of the delivery of the placenta. The persistent circulating levels of VEGFR-2 suggest a maternal endothelial origin of this peptide. The decreased VEGFR-2 plasma levels in preeclamptic women may serve as a marker of endothelial dysfunction. [less ▲]

Detailed reference viewed: 78 (7 ULg)
Full Text
Peer Reviewed
See detailMT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis
Maquoi, Erik ULg; Assent, Delphine; Detilleux, Julien et al

in Oncogene (2012), 31(4), 480-93

As invading breast carcinoma cells breach their underlying basement membrane, they become confronted with a dense three-dimensional reactive stroma dominated by type I collagen. To develop metastatic ... [more ▼]

As invading breast carcinoma cells breach their underlying basement membrane, they become confronted with a dense three-dimensional reactive stroma dominated by type I collagen. To develop metastatic capabilities, invading tumor cells must acquire the capacity to negotiate this novel microenvironment. Collagen influences the fate of epithelial cells by inducing apoptosis. However, the mechanisms used by invading tumor cells to evade collagen-induced apoptosis remain to be defined. We demonstrate that membrane type-1 matrix metalloproteinase (MT1-MMP/MMP-14) confers breast cancer cells with the ability to escape apoptosis when embedded in a collagen gel and after orthotopic implantation in vivo. In the absence of MMP-14-dependent proteolysis, type I collagen triggers apoptosis by inducing the expression of the pro-apoptotic Bcl-2-interacting killer in luminal-like breast cancer cells. These findings reveal a new mechanism whereby MMP-14 activity promotes tumor progression by circumventing apoptosis. [less ▲]

Detailed reference viewed: 96 (25 ULg)
Full Text
Peer Reviewed
See detailIndividual decisions in placenta increta and percreta: a case series.
CHANTRAINE, Frédéric ULg; NISOLLE, Michelle ULg; PETIT, Philippe ULg et al

in Journal of Perinatal Medicine (2012), 40(3), 265-70

Abstract Objective: Placenta increta or percreta is an uncommon pathology, sometimes associated with high maternal morbidity. Its prevalence increases proportionally to the number of cesarean sections ... [more ▼]

Abstract Objective: Placenta increta or percreta is an uncommon pathology, sometimes associated with high maternal morbidity. Its prevalence increases proportionally to the number of cesarean sections. This study analyzed the changes of our management strategy to devise treatment guidelines for this uncommon disorder. Materials and methodology: Between 2005 and 2011, 10 cases of placenta increta or percreta were managed at our university hospital maternity department. Results: Among the 10 cases, seven were diagnosed prenatally. Two patients were diagnosed early, at 14 and 17 weeks of gestational age, and their pregnancies were terminated. Five had hysterectomies during the intrapartum period, and despite attempted conservative treatment for the two others, hysterectomy proved necessary 2 months postpartum because of intrauterine infections. Seven of the 10 women had hysterectomies. Conclusion: Prenatal diagnosis of placenta increta or percreta is essential to plan the delivery in a competent tertiary care center. The decision to perform a cesarean hysterectomy or leave the placenta in situ for spontaneous delivery is based on the extent of infiltration, the patient's hemodynamic status, and her desire to remain fertile. The high-risk of infection and severe hemorrhage must not be overlooked should conservative treatment be chosen. This situation requires prolonged close monitoring. [less ▲]

Detailed reference viewed: 113 (7 ULg)
Full Text
Peer Reviewed
See detailAnalgésie péridurale obstétricale et lombalgie du post-partum: un lien de cause à effet?
CHARLIER, Vanessa ULg; Brichant, Géraldine ULg; DEWANDRE, Pierre-Yves ULg et al

in Revue Médicale de Liège (2012), 67(1), 16-20

backache is a common problem in the general population. the prevalence of backpain is increased during pregnancy and after delivery. early studies have suggested that labor epidural analgesia might be ... [more ▼]

backache is a common problem in the general population. the prevalence of backpain is increased during pregnancy and after delivery. early studies have suggested that labor epidural analgesia might be associated with an increased incidence of backache in the postpartum period. However, these initial studies were retrospective and their design included several methodological deficiencies. All the prospective studies published afterwards (prospective cohort studies and 3 ran- domized controlled trials) yield the same result : there is no relationship between labor epidural analgesia and long-term postpartum backpain. pregnant women must be aware of this in order to make an informed and appropriate choice about labor epidural analgesia, the most effective technique for intra- partum pain relief. [less ▲]

Detailed reference viewed: 348 (21 ULg)
Full Text
Peer Reviewed
See detailIsoform 111 of vascular endothelial growth factor (VEGF111) improves angiogenesis of ovarian tissue xenotransplantation
Labied, Soraya ULg; Delforge, Yves ULg; Blacher, Silvia ULg et al

in Journal of Assisted Reproduction & Genetics (2012), 28(11), 1009

Detailed reference viewed: 38 (15 ULg)